Yves Aubin

Yves Aubin

Auto-generated profile, based on publicly available information

Yves Aubin

Centre for Oncology, Radiopharmaceuticals and Research, Biologics and Radiotherapeutic Drugs Directorate, Health Canada, Ottawa, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2018 in mAbs
Verified
Journal Article
Open access
RBRobert Brinson
Robert Brinson
JMJohn P. Marino
John P. Marino
FDFrank Delaglio
Frank Delaglio
LALuke W. Arbogast
Luke W. Arbogast
RERyan M. Evans
Ryan M. Evans
MWMats Wikström
Mats Wikström
The increased interest in using monoclonal antibodies (mAbs) as a platform for biopharmaceuticals has led to the need for new analytical techniques that can precisely assess physicochemical properties of these large and very complex drugs for the purpose of correctly identifying quality attributes (QA). One QA, higher order structure (HOS), is unique to biopharmaceuticals and essential for establishing consistency in biopharmaceutical manufacturing, detecting process-related variations from manufacturing changes and establishing comparability between biologic products. To address this measurement challenge, two-dimensional nuclear magnetic resonance spectroscopy (2D-NMR) methods were introduced that allow for the precise atomic-level comparison of the HOS between two proteins, including mAbs. Here, an inter-laboratory comparison involving 26 industrial, government and academic laboratories worldwide was performed as a benchmark using the NISTmAb, from the National Institute of Standards and Technology (NIST), to facilitate the translation of the 2D-NMR method into routine use for biopharmaceutical product development. Two-dimensional 1H,15N and 1H,13C NMR spectra were acquired with harmonized experimental protocols on the unlabeled Fab domain and a uniformly enriched-15N, 20%-13C-enriched system suitability sample derived from the NISTmAb. Chemometric analyses from over 400 spectral maps acquired on 39 different NMR spectrometers ranging from 500 MHz to 900 MHz demonstrate spectral fingerprints that are fit-for-purpose for the assessment of HOS. The 2D-NMR method is shown to provide the measurement reliability needed to move the technique from an emerging technology to a harmonized, routine measurement that can be generally applied with great confidence to high precision assessments of the HOS of mAb-based biotherapeutics.

5 June 2015 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
YAYves Aubin
Yves Aubin
DHDerek J. Hodgson
Derek J. Hodgson
WTWilliam B. Thach
William B. Thach
GGGeneviève Gingras
Geneviève Gingras
SSSimon Sauvé
Simon Sauvé

1 January 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HGHouman Ghasriani
Houman Ghasriani
PBPascal J. F. Belcourt
Pascal J. F. Belcourt
SSSimon Sauvé
Simon Sauvé
DHDerek J. Hodgson
Derek J. Hodgson
DBDenis Brochu
Denis Brochu
YAYves Aubin
Yves Aubin
Enzymatic addition of GalNAc to isotopically labeled IFNα2a produced in Escherichia coli yielded the O-linked glycoprotein GalNAcα-[13C,15N]IFNα2a. The three-dimensional structure of GalNAcα-IFNα2a has been determined in solution by NMR spectroscopy at high resolution. Proton-nitrogen heteronuclear Overhauser enhancement measurements revealed that the addition of a single monosaccharide unit at Thr-106 significantly slowed motions of the glycosylation loop on the nanosecond time scale. Subsequent addition of a Gal unit produced Gal(β1,3)GalNAcα-[13C,15N]IFNα2a. This extension resulted in a further decrease in the dynamics of this loop. The methodology used here allowed the first such description of the structure and dynamics of an O-glycoprotein and opens the way to the study of this class of proteins.

1 January 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SSSimon Sauve
Simon Sauve
DBDaniel Buijs
Daniel Buijs
GGGeneviève Gingras
Geneviève Gingras
YAYves Aubin
Yves Aubin
The three-dimensional structure of PrP110-136, a peptide encompassing the conserved hydrophobic region of the human prion protein, has been determined at high resolution in dodecylphosphocholine micelles by NMR. The results support the conclusion that the (Ctm)PrP, a transmembrane form of the prion protein, adopts a different conformation than the reported structures of the normal prion protein determined in solution. Paramagnetic relaxation enhancement studies with gadolinium-diethylenetriaminepentaacetic acid indicated that the conserved hydrophobic region peptide is not inserted symmetrically in the micelle, thus suggesting the presence of a guanidium-phosphate ion pair involving the side chain of the terminal arginine and the detergent headgroup. Titration of dodecylphosphocholine into a solution of PrP110-136 revealed the presence of a surface-bound species. In addition, paramagnetic probes located the surface-bound peptide somewhere below the micelle-water interface when using the inserted helix as a positional reference. This localization of the unknown population would allow a similar ion pair interaction.

14 April 2020 in Analytical Chemistry
Verified
Journal Article
Closed access
KEKorth W. Elliott
Korth W. Elliott
HGHouman Ghasriani
Houman Ghasriani
WMWikstroem Mats
Wikstroem Mats
John GiddensJohn Giddens
John Giddens
YAYves Aubin
Yves Aubin
LALuke W. Arbogast
Luke W. Arbogast

1 May 2017 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
DHDerek J. Hodgson
Derek J. Hodgson
YAYves Aubin
Yves Aubin